AstraZeneca Hopes To Differentiate Benralizumab On Efficacy, Dosing Convenience
This article was originally published in The Pink Sheet Daily
Biologic for severe asthma meets primary endpoint in two pivotal studies, but greater detail will be needed to differentiate the drug from already-approved Nucala and Cinqair.
You may also be interested in...
Several antibody drugs are in late-stage development to treat severe asthma and could reach the market in the next two years. But competition for niche subsets of patients will be fierce, and tailoring the right medications to the right patients to justify the higher cost of treatment will require advances in biomarker development.
Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.
Justices cite changing circumstances, constitutional concerns in preventing government from seeking dismissal of a case in which it initially declined to intervene. They also question whether government should intervene before moving to dismiss.